Alterations of NF-kB family members have been found to be associated with various forms of lymphoid malignancies. In order to determine whether alterations of the RelA gene are involved in lymphomagenesis, we analysed a large and representative panel (200 cases) of such tumors. Southern blot analysis did not reveal any rearrangements or locus ampli®cation, suggesting that structural alterations of the RelA gene may represent rare events in lymphoid neoplasia. By means of PCR-SSCP analysis, we were able to identify a single point mutation leading to amino acid substitution (codon 494, Glu-Asp) in the transactivating (TA) domain in one case of multiple myeloma. The mutated allele was expressed in the pathological bone marrow sample but not in the peripheral blood cells of the patient. We demonstrate that the RelA protein carrying this speci®c mutation (called RelA 494D ) has less transactivating ability than the normal RelA protein. Interestingly, the mutated protein has a lower anity for kB binding sites both as a homodimer or in association with the NFKB1/p50 subunit. Transfection experiments using a Gal4-RelA 494D fusion protein indicated that the mutation does not alter the intrinsic transactivating ability of the TA domain of RelA. Furthermore, in vitro translated RelA 494D is able to dimerize eciently with other NF-kB members, such as p50, cREL and IkBa. Our data therefore suggest that
Introduction
The NF-kB transcription factor family consists of a group of homodimeric and heterodimeric protein complexes which are involved in the regulation of a large variety of cellular and viral genes. In most cell types, NF-kB complexes (the prototype is the heterodimer p50/p65) are found in the cytoplasm as inactive forms, associated with a class of inhibitor proteins called IkBs. The activation of NF-kB may follow a wide variety of extracellular stimuli that lead to the phosphorylation, dissociation and subsequent degradation of IkB, thereby allowing NF-kB to be translocated to the nucleus where it can bind to speci®c cis-acting consensus sequences (kB sites) located in the promoters and enhancers of inducible genes (for reviews see Baeuerle and Henkel, 1994; Grilli et al., 1993; Siebenlist et al., 1994) .
In mammals, ®ve dierent members of the NF-kB system have been identi®ed: c-Rel, p65/RelA, RelB, p50/p105 (NFKB1), and p52/p100 (NFKB2). These proteins all share a highly conserved amino-terminal domain of approximately 300 amino acids (the rel homology domain), which contains the DNA-binding domain, the dimerization domain and the nuclear localization signal. NF-kB activity is controlled by its association with the family of IkB proteins, including IkBa/Mad-3, IkBb, IkBg, and the product of the putative proto-oncogene bcl-3, which are all characterized by the presence of a domain of 5 to 7 ankyrin-like repeats within their carboxy-terminal region (for review, see Verma et al., 1995) .
Various evidences suggest that members of the NFkB family may play a role in cell transformation. NFkB complexes are involved in the induction of gene encoding hematopoietic growth factors (e.g. IL-2, IL-6, G-CSF and GM-CSF), as well as growth control proteins (p53, c-myc, ras) (for review see Baeuerle and Henkel, 1994) . Increased NF-kB activity occurs in response to a variety of growth stimuli, and this has been implicated in the proliferation of murine ®broblasts transformed by the p40Tax protein of human T-cell leukemia virus 1 (Kitajima et al., 1992) . Finally, NF-kB genes have been implicated in tumorigenesis; particularly, in the pathogenesis of lymphoid malignancies. v-Rel, the viral homolog of cRel, can cause lymphoid tumors in chickens and transform immature and mature avian lymphoid cells in vitro (Gilmore, 1991; Bose, 1992) . c-Rel gene has been found to be rearranged in some cases of lymphoid neoplasia (Lu et al., 1991) , whereas ampli®cation is frequently associated with extranodal diuse large cell lymphomas (DLCL) (Houldsworth et al., 1996) . Rearrangements of the NFKB2/lyt-10 gene can be found at low frequency in B-cell lymphoma, B-cell chronic lymphocytic leukemia (B-CLL) and multiple myeloma (MM), and more commonly in cutaneous lymphomas (CL), as a consequence of chromosomal translocations or, more frequently, internal deletions (Neri et al., 1991; Fracchiolla et al., 1993; Migliazza et al., 1994) . The bcl-3 gene has been found to be involved in a t(14;19) chromosomal translocation in some cases of clinically aggressive B-CLL (Ohno et al., 1990) .
The possible involvement of RelA gene in tumorigenesis is suggested by a number of observations. First, a naturally occurring splice variant, called p65D, has been reported to transform a mammalian cell line (rat-1) in vitro . This variant form, more widely expressed than RelA in primary hematopoietic cells, lacks amino acids 222 ± 231 in a portion of RelA required for dimerization. This deletion abrogates the DNA-binding ability of RelA, probably by preventing homo-or heterodimeric association with a second NF-kB subunit . However, the transforming potential of p65D still remains to be clari®ed, as no signi®cant transforming potential in rat-1 cells has been reported by other authors (Grimm and Baeuerle, 1994) . Secondly, RelA plays an important role in the regulation of the expression of cell adhesion molecules and integrins, in particular the CD11b integrin (Sokoloski et al., 1993) , and it has been demonstrated that RelA antisense oligomers reduce the cell adhesion of many transformed cell lines and their growth in vivo (Higgins et al., 1993) . Finally, the RelA locus has been mapped on chromosome 11q13 (Mathew et al., 1993) , a region that has been found to be involved in nonrandom chromosomal translocations such as t(11;14)(q13;q32) in non-Hodgkin lymphomas and multiple myelomas (Van den Berghe et al., 1979; Lai et al., 1995) , or ampli®cations in various types of solid tumor (Motokura and Arnold, 1993) . Recently, ampli®cation of the RelA locus has been found in a few cases of B-cell lymphomas (Houldsworth et al., 1996) .
These considerations prompted us to perform a comprehensive molecular analysis of the RelA gene in a representative panel of 200 lymphoid malignancies. Although no structural alterations involving the RelA locus were detected, we were able to identify a missense point mutation in the transactivating domain of RelA in one case of MM. We have demonstrated that this mutation is associated with the neoplastic clone and that a RelA mRNA harboring the point mutation is transcribed in malignant cells. Functional analysis indicated that this tumor-associated mutation alters the DNA-binding and transcriptional activities of the RelA protein. The data presented here may provide more insight into the characterization of the amino acid sequences and protein structures involved in mediating the biological activities of RelA.
Results

Structural alterations of the RelA locus do not occur in lymphoid malignancies
Rearrangements of the RelA locus were investigated by Southern blot analysis using as a probe the full-length RelA cDNA clone (Ruben et al., 1991) Detection of a missense point mutation in the transactivating domain of RelA in one case of mature B-cell neoplasm
The absence of structural alterations involving the RelA locus prompted us to investigate the presence of other molecular lesions, such as point mutations and/ or small insertions/deletions, in the functional domains of the RelA gene. In particular, we investigated the carboxy-terminal transactivation (TA) domain on the basis of the following considerations. First, it has been shown that structural alterations of c-Rel in lymphoid malignancies involve the carboxy-terminal TA domain. Secondly, the TA domain of RelA is entirely coded by the last exon of the gene (Deloukas and van Loon, 1993 ; our unpublished results), thus allowing the in vitro ampli®cation of this region using genomic DNA.
The analysis was performed using the PCR-SSCP method on the same panel of cases listed in Table 1 . Since it has been demonstrated that the sensitivity of SSCP assays is greatly reduced if the analysed PCR ampli®ed products are longer than 200 nucleotides (Orita et al., 1989) , we generated two pairs of primers to amplify two overlapping fragments (Figure 1a ) of 132 and 159 nucleotides respectively (see also Materials and methods). The ampli®ed fragments included part of the TA2 domain (amino acids 459 to 520) and the entire TA1 domain (amino acids 521 to 550) (Schmitz and Baeuerle, 1991) . The results of PCR-SSCP analysis are shown in Table 1 . A dierent migrating pattern was observed only in the DNA from the bone marrow sample of one patient (LB405) aected by multiple myeloma, a malignant clonal proliferation of plasma cells (Figure 1b) . To determine the exact nature of the mutation, we performed the direct DNA sequencing of the PCR-ampli®ed fragment, which revealed a single base pair change (G to C) leading to amino acid substitution at codon 494 (GAG-GAC, Glu-Asp) (Figure 1c ). We next demonstrated that this mutation was not detectable in the DNA from the peripheral blood lymphocytes (PBL) or isolated granulocytes from the same patient (data not shown). These data, together with the absence of mutations in a panel of DNA from 30 normal controls (data not shown), suggest that such a mutation does not represent a rare polymorphism, but rather a genetic lesion associated with this particular case of malignancy. Furthermore, we used RT/PCR to investigate whether the mutated RelA allele was transcribed in the bone marrow plasma cells, by using oligonucleotide primers (see Materials 
Mutant form of RelA gene in multiple myeloma D Trecca et al and methods and Figure 1a ) to amplify cDNA from LB405 RNA. Direct sequence analysis of the PCR product revealed the presence of the mutation at codon 494, indicating that the altered RelA allele (named RelA
494D
) was transcribed in this speci®c case ( Figure 1c) . Notably, the mutation occurs in a stretch of 14 amino acids (residues 490 ± 454) almost identical beween human, mouse, and chicken (twelve amino acids out of fourteen); however, the Glu-494 is conserved only between human and mouse RelA proteins and is substituted with a serine in chicken RelA ( Figure 1d ).
Transcriptional activity of RelA
494D
To test the consequences of this point mutation in the transactivation potential of RelA, we constructed a vector capable of expressing a complete RelA protein containing the speci®c mutation at codon 494. Because of the degraded status of RNA from case LB405, we ®rst constructed a full length mutated RelA cDNA by replacing the carboxy-terminal region (nucleotides corresponding to the SalI-SmaI fragment) with the same region generated from the tumor RNA by the PCR ampli®cation of reverse transcribed cDNA (see Materials and methods). The full length RelA 494D was inserted into the expression vector pRcCMV in both sense and antisense orientations.
We tested the ability of RelA 494D to stimulate the transcription of a reporter gene linked to a minimal promoter and speci®c kB sequences. Plasmid vectors expressing the normal and mutated RelA proteins were cotransfected, alone or in combination, with the pMPuPA-HIV reporter plasmid, in which the HIVkB sequences were linked upstream to the minimal urokinase (uPA) gene promoter and CAT coding sequences (Hansen et al., 1994) . CAT activity was measured as a function of kB-dependent transcription. Simian Cos7 cells were used in the transfection experiments since they have low levels of endogenous NF-kB activity (Schmitz and Baeuerle, 1991) The functional properties of the TA domain are not altered by the mutation We next investigated whether the reduced transactivation activity of RelA 494D was a consequence of an impairment of the TA domain due to the amino acid substitution at position 494. The transcriptional activity of the TA domain of RelA 494D was assessed by making a construction of chimeric proteins containing the DNAbinding domain of the yeast transcriptional activator protein Gal4. In particular, we fused the C-terminal transactivation domain of the normal and mutated RelA Figure  3 ). HeLa cells were transfected with Gal4 fusion constructs together with the Gal4-dependent reporter plasmid pG5E1CAT. As indicated in Figure 3 , both the normal and the mutated fusion proteins were able to induce transcription at a similarly high level, suggesting that the mutation at codon 494 does not alter the intrinsic transactivating potential of RelA.
Altered transactivating activity of RelA 494D is associated with reduced DNA-binding ability
To investigate the functional properties of the Rel 494D protein further, we tested its DNA-binding activity using nuclear extracts obtained from transiently transfected Cos7 cells in an electrophoretic mobility shift assay (EMSA). As shown in Figure 4 , RelA , lane 4), and the ®ndings were similar in extracts from cells cotransfected with pCMVp50 and pCMV-RelA (lanes 5 to 7). Densitometric analysis of the gel shift indicated a ®vefold reduction in the binding ability of mutated RelA homodimers in comparison with the wild type, whereas the reduction in p50/RelA 494D heterodimers was only twofold that of the p50/RelA complexes. Nuclear extracts used in these experiments contained comparable levels of the transfected proteins as assessed by Western blot analysis (data not shown). Supershift assays using p50 or RelA antisera con®rmed the speci®city of the NF-kB complexes (lanes 10, 13 and 14).
The reduced DNA-binding activity of the mutated RelA protein does not appear to be dependent on the kB sequence used as a probe in EMSA, as similar results were obtained in the same experimental conditions using other distinct kB target sequences, such as the HLA and IL-2 receptor (IL-2R) kB sites and the kB2 consensus site located in the promoter region of the NFKB2 gene (Lombardi et al., 1995) (data not shown).
To characterize the anity of the RelA 494D protein for kB sites in more detail, we determined its dissociation rate (o-rate) in a competition assay. In vitro translated normal and mutated RelA proteins were incubated with the labeled HIV-kB oliogonucleotidic probe, and aliquots from the same DNA-binding 494D and p50 expression vectors, alone or in combination, to test their ability to transactivate a kB-dependent reporter gene. The transfections were performed using 0.3 pmoles of the indicated expression vector and 0.5 pmoles of HIV-kB CAT as reporter plasmid. Activity is referred as fold induction in comparison with the basal levels (mock transfectants). The results shown here are representative of three independent transfection experiments with each transfection performed in triplicate reaction were loaded at dierent time points (0, 3, 6, 9, 12, 15 and 18 min) after the addition of 1006unlabeled competitor. Because of the dierent DNA-binding ability of the normal and mutated RelA protein (see above and Figure 4) , we modi®ed the EMSA conditions (see Materials and methods) in order to obtain comparable initial levels of bound complexes. In particular, we used dierent amounts of in vitro translated RelA (2 ml) and RelA 494D (3 ml) as previously determined by titration in EMSA (data not shown). The dissociation rate of the DNA-binding complexes was determined by means of densitometric analysis, plotting the amount of undissociated factor against time after the addition of the cold competitor. As shown in Figure 5a , RelA 494D homodimers dissociated more rapidly from the labeled probe than the RelA homodimers. In particular, 50% of the RelA 494D complexes dissociated from the HIV-kB probe in about 10 min, while the same fraction of RelA complexes was released in 13 min. After 18 min, only 25% of the initial binding activity was still detected in the case of the RelA 494D homodimers, whereas about 50% of the RelA complexes were still bound to the labeled probe (Figure 5b ). It should be considered that, due to the dierent amounts of normal and mutated RelA proteins used in the assay, the instability of the RelA 494D -containing complexes is probably underestimated.
The mutation does not in¯uence the dimerization properties of RelA 494D EMSA analysis indicated that RelA 494D is capable of interacting with p50 subunit (Figure 4) . To provide more evidence of the ability of RelA 494D to dimerize with NF-kB proteins, we used the in vitro translated RelA and RelA 494D proteins in co-immunoprecipitation experiments with in vitro translated p50, cRel and IkBa/Mad-3 proteins. As shown in Figure 7 , where protein complexes were immunoprecipitated with a RelA antibody, RelA 494D dimerized with p50, IkBa and c-Rel (lanes 6, 9 and 12) at a similar level to that of RelA, suggesting that the mutation does not aect the dimerization ability of RelA
. Similar results were obtained when co-immunoprecipitations were carried out with speci®c p50, cRel and IkBa antibodies, respectively (data not shown).
The DNA-binding ability of RelA 494D is inhibited by IkBa
It has been reported that sequences within the carboxyterminal domain of RelA are necessary for a productive inhibitory interaction with IkBa (Ganchi et al., 1992) . Therefore, we investigated whether the DNA binding activity of RelA 494D could still be inhibited by IkBa. The same in vitro cotranslated proteins used in Figure 6 were incubated with a labeled HIV-kB oligonucleotide probe and used in EMSA. In order to obtain comparable level of bound complexes, the EMSA conditions were modi®ed according to the procedure used in Figure 5 . The EMSA analysis reported in Figure 7 shows that both RelA and RelA 
Discussion
A number of reports have provided evidence that structural alterations of members of the NF-kB transcription factor family, such as genomic rearrangements or gene ampli®cation, are associated with certain types of lymphoid malignancies. This evidence prompted us to investigate a possible involvement of the RelA gene in a large and representative panel of these tumors. Although we found no structural alterations of the RelA locus, we did identify a single case of MM in which a point mutation in the transactivating (TA) domain of the gene had led to an amino acid substitution. Analysis of its functional features indicates that this tumorassociated mutant form of RelA has reduced DNAbinding and transactivating abilities.
Evidence of a direct involvement of the RelA gene in lymphoid malignancies is limited to a recent study reporting the ampli®cation of the RelA locus in a few cases of DLCL lymphoma (5/111) (Houldsworth et al., 1996) . In our series, which was representative of the malignant counterpart of the dierent stages of maturation and dierentiation of B and T lymphocytes and included nine cases of DLCL, no rearrangement or ampli®cation of the RelA gene were found. The absence of ampli®cation in our DLCL cases may be related to the small number of cases investigated. Our PCR-SSCP approach in investigating other types of molecular lesions aecting RelA in lymphoid malignancies allowed the identi®cation of a point mutation in one case of MM. Our data seem to exclude the possibility of a rare case of polymorphism, since we found the mutation only in the plasma cell enriched bone marrow population of the patient and not in the peripheral granulocytes. In addition, the mutation was not detected in DNA taken from 30 healthy controls. The RelA mutation therefore appears to be acquired rather than somatic, and to be associated with the tumoral lymphoid population. Both the mutated and normal alleles were expressed at similar levels in the plasma cell enriched population, as shown by means of RT-PCR/direct sequencing analysis.
The RelA mutation identi®ed in the present study occurs at codon 494 within the carboxy-terminal TA
RelA/RelA - Figure 7 IkBa inhibits the DNA-binding activity of RelA 494D . In vitro translated proteins were used in EMSA to test whether RelA 494D was still inhibited by IkBa as RelA. An HIV-kB oligonucleotide was used as probes with 3 ml of RelA 494D and 2 ml of RelA to obtain comparable levels of bound complexes (see Materials and methods). C: the reticulocyte lysate used as control. RelA homodimers are indicated on the left pCMV pCMV-RelA pCMV-RelA 494D Figure 8 Overexpressed RelA 494D is localized at cytoplasmic level. Cos7 cells were transfected with the indicated expression vectors. Immuno¯uorescence analysis was performed using an antibody speci®c for the C-terminal region of RelA domain, which has been localized between amino acids 416 and 550 Moore et al., 1993; Blair et al., 1994) . This domain is highly conserved throughout species; 86% and 37% amino acids of human p65 protein are identical to those of mouse and chicken RelA respectively (Nolan et al., 1991; Ikeda et al., 1993) . Three independent and cooperating acidic activating modules (AAMs) have been identi®ed in this region (Moore et al., 1993; Blair et al., 1994) . In particular, each module consists of bulky, mainly acidic hydrophobic amino acids, surrounding a phenylalanine residue; mutation of phenylalanines 444, 473 and 541 reduces or abrogates the transcriptional activity of RelA (Blair et al., 1994) . Furthermore, phenylalanine 444 is contained within a leucin zipper-like (LZ) motif (aa 443 to 451), a domain involved in protein-protein interactions; disruption of this motif by means of site directed mutagenesis completely abolishes the transcriptional activity of RelA Moore et al., 1993) . Our analysis indicates that RelA 494D has less transactivating ability (about 50%) than normal RelA; however, the amino acidic substitution within the TA domain does not seem to alter its intrinsic transactivating potential, as shown by the ability of the Gal4-RelA 494D fusion protein to fully activate a reporter plasmid containing Gal4-responsive elements. On the basis of our EMSA experiments, and in particular the dissociation rate analysis, it is conceivable that the altered transactivating ability of RelA 494D is a result of its reduced DNA-binding ability, observed in both the homodimeric and heterodimeric forms. However, it must be pointed out that an association with p50 reduces the binding instability of RelA . Our co-immunoprecipitation experiments using in vitro translated proteins indicate that RelA 494D is able to dimerize eciently with other members of the NF-kB system. This ®nding is further supported by the evidence of the cytoplasmic subcellular localization of RelA 494D in transfected Cos7 and HeLa cells, which indicates its ability to associate with IkB proteins in vivo. It has been reported that the carboxy-terminal TA domain sequences of RelA are necessary (Ganchi et al., 1992) for a productive inhibitory interaction with IkBa; our in vitro experiments shown in Figure 7 suggest that RelA 494D can still have its DNA-binding activity inhibited by IkBa.
We suggest that the mutation at position 494 may alter a speci®c structural conformation of the RelA protein needed for proper DNA interaction. Although our data do not address this speci®c issue, it is interesting to note that computer-assisted analysis of the secondary structure of the mutated RelA protein, performed using the Garnier protein structure prediction method (Garnier et al., 1978) , indicated that the presence of an aspartic acid instead of glutamic acid at position 494 may alter the predicted a-helical structure of the region between amino acids 490 and 500. Knowledge of the tertiary structure of RelA protein would be helpful in further elucidating this issue.
The biological consequences of the mutation identi®ed in this study remain to be clari®ed. Our data suggest that RelA 494D may act as a`negative' mutant, and it would therefore be expected to downmodulate the kB-dependent transactivation of targeted genes in vivo. In addition, it can be speculated that RelA 494D exerts its negative eect by destabilizing DNA-bound enhancer complexes. It has been demonstrated that NF-kB complexes are able to synergize with many transcription activators and/or repressors (i.e. c-Jun/c-fos, C/EBP and other bZIP proteins), including general elements of the basal transcriptional machinery (Nolan, 1994) .
With regard to the possible transforming potential of RelA
494D
, preliminary experiments in our laboratory indicate that Rel 494D cannot induce either focus formation or growth in soft agar of stably transfected rat-1 cells (data not shown). These observations are in agreement with the failure of p65D to transform ®broblasts as previously reported (Grimm and Baeuerle, 1994) . However, it would be important to test the transforming potential of RelA 494D in a more appropriate context, such as its transfection into lymphoblastoid cell lines.
In conclusion, our data indicate that RelA gene alterations are rarely involved in lymphoid malignancies. This is in contrast with the more frequent involvement observed for other members of the NFkB family, such as NFKB2/lyt-10, c-Rel and bcl-3. The reasons of this are merely speculative at the moment. It has been observed that RelA protein is not appreciably expressed and active in mature B lymphocytes (Liou et al., 1994) . In addition, knock-out experiments in mice have shown that RelA-de®cient embryos die of massive liver degeneration as a consequence of hepatocyte death by apoptosis, whereas no alteration in the hematopoietic precursors has been noticed (Beg et al., 1995) . This evidence suggests that RelA, unlike other members of the NF-kB family, such as NFKB2 and RelB, may play a limited biological role in B and T cell growth and dierentiation. On the other hand, the dramatic eect of RelA knock-out indicates that it has a broader transactivating spectrum, than the other members of the NF-kB family, and re¯ects the importance of ®ne regulation to its activity. Alterations greatly aecting RelA functions would probably not be biologically tolerated and therefore would not be found to be associated with malignant cell proliferations.
Materials and methods
Pathological samples, DNA preparation and Southern blot analysis
Pathological samples from 200 dierent lymphoid malignancies were collected during standard diagnostic procedures. Mononuclear cell fractions from malignant bone marrow, lymph nodes or peripheral blood were obtained by means of Ficoll-Hypaque gradient separation. The same method was used to separate mononuclear cell and granulocytes from the peripheral blood of patient LB405. DNA was obtained by mean of proteinase K digestion, phenol-chloroform extraction and ethanol precipitation. RNA was extracted using the guanidine isothiocyanate method (Sambrook et al., 1998) ; the DNAs were digested with BamHI or EcoRI restriction enzymes. Southern blot analysis was performed as previously reported (Fracchiolla , 1993) . The ®lters were hybridized with the full-length RelA cDNA (Ruben et al., 1991) . RelA locus ampli®cation was investigated by hybridizing the same ®lters with the trk gene cDNA, as an arbitrary probe (Greco et al., 1992) . Densitometric analysis was performed using a GS-670 Imaging Densitometer (Bio-Rad).
PCR-SSCP and direct sequencing analysis
Two pairs of primers, amplifying the RelA sequences (Ruben et al., 1991) corresponding to amino acids 459 to 503 (TA5 5'-CAGCTGTGTTCACAGACCTG-3', TA3/2 5'-CACTAGGCGAGTTATAGCCTC-3') and amino acids 497 to 550 (TA5/2 5'-GAGGCTATAACTCGCCTAGTG-3' and TA3 5'-CTTAGGAGCTGATCTGACTC-3') were designed and used for the PCR ampli®cation of genomic DNA. The PCR-SSCP analyses and direct sequencing were performed as previously described . Brie¯y, 100 ng of genomic DNA were used as a template for PCR reactions and ampli®cation was for 30 cycles in an automated thermal cycler (Perkin Elmer). Each cycle consisted of denaturation (15 s at 948C), annealing (15 s at 658C) and extension (30 s at 728C). The cDNAs from normal and pathological samples were obtained by RT-PCR with Superscript TM (Gibco BRL) using a TA3 primer for the ®rst strand synthesis. Second strand synthesis was performed as suggested by the manufacturer. cDNA ampli®cation was performed as described above, using the TA5 and TA3 primers; direct sequencing was performed using the same primers in both orientations.
Plasmid vectors
The sequence corresponding to the C-terminal region of the mutated RelA (amino acids 459 to 550) was ampli®ed with primers TA5 and TA3 (as above) from the cDNA of patients LB405. The PCR ampli®ed fragment was digested with SalI and SmaI restriction enzymes and substituted for the corresponding normal fragment of RelA full-length cDNA cloned into Bluescript vector (Promega). Normal and mutated RelA cDNAs were excised from Bluescript vectors and ligated into the HindIII-XbaI cloning sites of the pRcCMV expression vector (Invitrogen). pCMV-p50, pCMV-cRel and pCMV-IkBa/Mad-3 have been previously described (Hansen et al., 1992) , as has the HIV-kB CAT (pMPuPA-HIV CAT) (Hansen et al., 1994) . To obtain Gal4-RelA fusion protein, normal and mutated RelA Cterminal domains (amino acids 416 to 550) were ampli®ed from pCMV-RelA plasmids with speci®c primers (Gal5 5'CGGGATCCCGCCTCCTCAGGCTGTG-3', which introduces a BamHI site (underlined), and Gal3 5'-GCTCTAGAGCTTAGGAGCTGATCTG-3', which contains an XbaI site (underlined)), and cloned into the BamHI-XbaI sites of the pSG424 plasmid (Sadowski and Ptashne, 1989) downstream to and in frame with the Gal4 DNA-binding domain (amino acids 1 to 147 of the yeast gene Gal4). pG5E1CAT contains ®ve Gal4 DNA-binding sites (GalUAS) upstream to the adenovirus minimal E1 promoter element and linked to the CAT gene. pG0E1CAT contains no GalUAS (Blair et al., 1994) . The plasmid sequences were con®rmed by sequencing using a Sequenase sequencing kit (Amersham).
Cell culture and tranfection
HeLa and Cos7 cells were maintained in Dulbecco's Modi®ed Eagle Medium (DMEM), supplemented with 10% heat-inactivated fetal calf serum. 2610 5 cells were plated on 60 mm dishes and transfected by means of the calcium phosphate method (Sambrook et al., 1989) . The cells were transfected with 0.5 pmoles of reporter plasmid and 0.3 pmoles of expression vectors. For Gal4-RelA fusion protein transactivating analysis, HeLa cells were transiently transfected with 0.5 pmoles of the indicated expression vectors and 0.3 pmoles of reporter plasmid. Cells were harvested 48 h after transfection and equal amounts (20 mg) of nuclear extracts were used for CAT assay. Transcriptional activity was determined by means of the liquid scintillating method (Sambrook et al., 1989) . The results shown here are representative of three independent transfection experiments with each transfection performed in triplicate. Experimental variability was less than 15%.
Electrophoretic mobility shift assay and competition analysis
Nuclear and cytosolic extracts from the transfected cells were prepared as described by Dignam et al. (1983) . HIV-LTR, HLA, IL-2R and NFKB2-kB2 oligonucleotide probe sequences are reported elsewhere (Nabel and Baltimore, 1987; Chang et al., 1994; Ballard et al., 1988; Lombardi et al., 1995) . For each reaction, 2 mg of nuclear extract were incubated for 20 min at room temperature with 30 kcpm of 32 P-labeled oligonucleotides in the presence of 2 mg poly (dIdC) (Boehringer Mannheim Biochemia). 1006cold competitor was added when indicated. 1 ml of the indicated antibody (Santa Cruz Biotechnology, 100 mg/0.1 ml) was used in the supershift experiments. Samples were loaded on a 0.256TBE-4% polyacrylamide gel (16TBE=89 mM Tris, 90 mM boric acid and 1 mM EDTA). The gels were run for 2 ± 3 h at room temperature in 0.256TBE at 300 Volts, dried and exposed 1 ± 2 days for autoradiography at 7808C. For the dissociation rate analysis in vitro translated RelA proteins were used and DNA-binding reactions were performed as described above, except that: (i) 3 ml of RelA 494D and 2 ml of RelA were used; (ii) 1 ml of poly (dIdC) was used, in order to increase the amount of bound RelA complexes; (iii) the samples were loaded at the indicated time points after the addition of 1006cold competitor; (iv) electrophoresis was performed at 48C. The densitometric analyses were performed using a GS-670 Imaging Densitometer (Bio-Rad).
In vitro transcription and translation and co-immunoprecipitation analysis
The pCMV-RelA, pCMV-RelA 494D , pCMV-p50, pCMVcRel and pCMV-IkBa/Mad-3 expression vectors were transcribed and translated, alone or in combination, using the TNT TM Coupled Reticulocyte Lysate System (Promega) in the presence of 35 S-methionine. To determine translation eciency, 2 ml of each reaction were loaded on an 8% SDS-polyacrylamide gel. The labeled proteins (7 ml of lysate) were incubated for 3 h at 48C with 1 ml of RelA antibody, diluted to 250 ml with RIPA Buer (150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris pH 7.5 and 5 mM EDTA) and rotated for 12 h at 48C in the presence of 10% protein A-Sepharose (Sigma). The immunocomplexes were washed three times with RIPA buer, heat denatured (5 min at 1008C), separated on an 8% SDS-polyacrylamide gel, ®xed in 10% acetic acid, treated with Amplify enhancer (Amersham) and fluorographed.
Immuno¯uorescence analysis
Immuno¯uorescence analysis was performed as previously described (Migliazza et al., 1994) using the RelA antibody. The slides were analysed by means of confocal laser scanning microscopy. The images were collected and elaborated using Confocal Laser Microscope Operating Software MRC600 (Bio-Rad).
